Clinical Trials
These are the clinical trials currently available in the UK in respect of ALK-positive lung cancer.
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (USZ-STRIKE)
Multi-modality local consolidative treatment (LCT) versus conventional care of advanced lung cancer after first line systemic anti-cancer treatment (RAMON)
A Study of NVL-655 (new ALK TKI targeting ALK and resistance mutations) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Lorlatinib with ALK-Positive NSCLC
(which has progressed on first-line certinib or alectinib)
Alectinib: Deciphering anti tumor response and resistance
with intratumor heterogenicity
(Darwin II)